Human urine proteomics: building a list of human urine cancer biomarkers

References

• Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev.88(2), 451–487 (2008).
   PubMed Web of Science ®Google Scholar
• Said J. Biomarker discovery in urogenital cancer. Biomarkers10(Suppl. 1), S83–S86 (2005).
   PubMed Web of Science ®Google Scholar
• Kentsis A, Monigatti F, Dorff K et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin. Appl.3(9), 1052–1061 (2009).
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol.7(9), R80 (2006).
   PubMed Web of Science ®Google Scholar
• Li QR, Fan KX, Li RX et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun. Mass Spectrom.24(6), 823–832 (2010).
   PubMed Web of Science ®Google Scholar
• Gonzales PA, Pisitkun T, Hoffert JD et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol.20(2), 363–379 (2009).
   PubMed Web of Science ®Google Scholar
• Agron IA, Avtonomov DM, Kononikhin AS et al. Accurate mass tag retention time database for urine proteome analysis by chromatography–mass spectrometry. Biochemistry75(5), 636–641 (2010).
   PubMed Web of Science ®Google Scholar
• Castagna A, Cecconi D, Sennels L et al. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res.4(6), 1917–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc. Natl Acad. Sci. USA101(36), 13368–13373 (2004).
   PubMed Web of Science ®Google Scholar
• Sun W, Li F, Wu S et al. Human urine proteome analysis by three separation approaches. Proteomics5(18), 4994–5001 (2005).
   PubMed Web of Science ®Google Scholar
• Wang L, Li F, Sun W et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell Proteomics5(3), 560–562 (2006).
   PubMed Web of Science ®Google Scholar
• Pieper R, Gatlin CL, McGrath AM et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics4(4), 1159–1174 (2004).
   PubMed Web of Science ®Google Scholar
• Tan LB, Chen KT, Yuan YC, Liao PC, Guo HR. Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J. Urol.28(1), 117–122 (2010).
   PubMed Web of Science ®Google Scholar
• Schaub S, Wilkins J, Weiler T et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int.65(1), 323–332 (2004).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol.7(3), 230–240 (2006).
   PubMed Web of Science ®Google Scholar
• Coon JJ, Zurbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl.2(7–8), 964 (2008).
   PubMed Web of Science ®Google Scholar
• Cannas A, Kalunga G, Green C et al. Implications of storing urinary DNA from different populations for molecular analyses. PLoS One4(9), e6985 (2009).
   Google Scholar
• Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol.25(8), 887–893 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W, Chait BT. ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal. Chem.72(11), 2482–2489 (2000).
   PubMed Web of Science ®Google Scholar
• Bakalarski CE, Haas W, Dephoure NE, Gygi SP. The effects of mass accuracy, data acquisition speed, and search algorithm choice on peptide identification rates in phosphoproteomics. Anal. Bioanal. Chem.389(5), 1409–1419 (2007).
   PubMed Web of Science ®Google Scholar
• Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods4(3), 207–214 (2007).
   PubMed Web of Science ®Google Scholar
• Casado-Vela J, Cebrian A, Gomez Del Pulgar MT et al. Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications. Proteomics11(4), 590–603 (2011).
   PubMed Web of Science ®Google Scholar
• Tamm I, Horsfall FL Jr. A mucoprotein derived from human urine which reacts with influenza, mumps, and Newcastle disease viruses. J. Exp. Med.95(1), 71–97 (1952).
   PubMed Web of Science ®Google Scholar
• Casado-Vela J, Rodriguez-Suarez E, Iloro I et al. Comprehensive proteomic analysis of human endometrial fluid aspirate. J. Proteome Res.8(10), 4622–4632 (2009).
   PubMed Web of Science ®Google Scholar
• Makarov A, Denisov E, Kholomeev A et al. Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer. Anal. Chem.78(7), 2113–2120 (2006).
   PubMed Web of Science ®Google Scholar
• Domon B, Aebersold R. Mass spectrometry and protein analysis. Science312(5771), 212–217 (2006).
   PubMed Web of Science ®Google Scholar
• Shen Y, Kim J, Strittmatter EF et al. Characterization of the human blood plasma proteome. Proteomics5(15), 4034–4045 (2005).
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Pfeiler G, Maurer N et al. Room temperature activates human blood platelets. Lab. Invest.81(4), 581–592 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med.13(10), 1176–1184 (2007).
   PubMed Web of Science ®Google Scholar
• McCarthy J, Hopwood F, Oxley D et al. Carbamylation of proteins in 2-D electrophoresis-myth or reality?. J. Proteome Res.2(3), 239–242 (2003).
   PubMed Web of Science ®Google Scholar
• Stark GR. Reactions of cyanate with functional groups of proteins. IV. Inertness of aliphatic hydroxyl groups. Formation of carbamyl- and acylhydantoins. Biochemistry4(11), 2363–2367 (1965).
   PubMed Web of Science ®Google Scholar
• Stark GR. Reactions of cyanate with functional groups of proteins. II. formation, decomposition, and properties of N-carbamylimidazole. Biochemistry4, 588–595 (1965).
   PubMed Web of Science ®Google Scholar
• Stark GR. Reactions of cyanate with functional groups of proteins. 3. Reactions with amino and carboxyl groups. Biochemistry4(6), 1030–1036 (1965).
   PubMed Web of Science ®Google Scholar
• Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat. Rev. Urol.7(1), 11–20 (2010).
   PubMed Web of Science ®Google Scholar
• Gilbert R. Taking a midstream specimen of urine. Nurs. Times102(18), 22–23 (2006).
   Google Scholar
• Picotti P, Lam H, Campbell D et al. A database of mass spectrometric assays for the yeast proteome. Nat. Methods5(11), 913–914 (2008).
   PubMed Web of Science ®Google Scholar
• Stahl-Zeng J, Lange V, Ossola R et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics6(10), 1809–1817 (2007).
   PubMed Web of Science ®Google Scholar
• Casado-Vela J, Ruiz EJ, Nebreda AR, Casal JI. A combination of neutral loss and targeted product ion scanning with two enzymatic digestions facilitates the comprehensive mapping of phosphorylation sites. Proteomics7(15), 2522–2529 (2007).
   PubMed Web of Science ®Google Scholar
• Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell138(4), 795–806 (2009).
   PubMed Web of Science ®Google Scholar
• Pritzker KP. Cancer biomarkers: easier said than done. Clin. Chem.48(8), 1147–1150 (2002).
   PubMed Web of Science ®Google Scholar
• Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights1, 1–48 (2007).
   PubMedGoogle Scholar
• Nagaraj N, Mann M. Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J. Proteome Res.10(2), 637–645 (2011).
   PubMed Web of Science ®Google Scholar
• Decramer S, Gonzalez de Peredo A, Breuil B et al. Urine in clinical proteomics. Mol. Cell Proteomics7(10), 1850–1862 (2008).
   PubMed Web of Science ®Google Scholar
• Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev. Proteomics6(5), 507–514 (2009).
   PubMed Web of Science ®Google Scholar
• Mohammed SI, Rahman M. Proteomics and genomics of urinary bladder cancer. Proteomics Clin. Appl.2(9), 1194–1207 (2008).
   PubMed Web of Science ®Google Scholar
• Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA102(21), 7677–7682 (2005).
   PubMed Web of Science ®Google Scholar
• Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br. J. Cancer96(10), 1569–1578 (2007).
   PubMed Web of Science ®Google Scholar
• Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur. J. Haematol.72(4), 252–258 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenzweig CN, Zhang Z, Sun X et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J. Urol.181(3), 1407–1414 (2009).
   PubMed Web of Science ®Google Scholar
• Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br. J. Cancer83(7), 847–852 (2000).
   PubMed Web of Science ®Google Scholar
• Tsujisaki M, Imai K, Hirata H et al. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin. Exp. Immunol.85(1), 3–8 (1991).
   PubMed Web of Science ®Google Scholar
• Altomonte M, Fonsatti E, Lamaj E et al. Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Res. Treat.58(1), 19–23 (1999).
   PubMed Web of Science ®Google Scholar
• Lei JY, Wang Y, Jaffe ES et al. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am. J. Dermatopathol.22(6), 524–529 (2000).
   PubMed Web of Science ®Google Scholar
• Pavlov N, Badet J. Angiogenin: involvement in angiogenesis and tumour growth. Bull. Cancer88(8), 725–732 (2001).
   PubMed Web of Science ®Google Scholar
• Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol. Oncol.96(2), 516–519 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng WL, Wang CS, Huang YH et al. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int. J. Cancer123(8), 1787–1796 (2008).
   PubMed Web of Science ®Google Scholar
• Reeves JR, Xuan JW, Arfanis K et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem. J.385(Pt 1), 105–114 (2005).
   PubMed Web of Science ®Google Scholar
• Begum FD, Hogdall CK, Kjaer SK et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res.24(3b), 1981–1985 (2004).
   PubMed Web of Science ®Google Scholar
• Brunner A, Ensinger C, Christiansen M et al. Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch.450(6), 659–664 (2007).
   PubMed Web of Science ®Google Scholar
• Arellano-Garcia ME, Li R, Liu X et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int. J. Mol. Sci.11(9), 3106–3121 (2010).
   PubMed Web of Science ®Google Scholar
• Guzinska-Ustymowicz K, Zalewski B, Kasacka I, Piotrowski Z, Skrzydlewska E. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. Anticancer Res.24(5A), 2847–2851 (2004).
   PubMed Web of Science ®Google Scholar
• Radisky ES. Cathepsin D. Regulation in mammary gland remodeling, misregulation in breast cancer. Cancer Biol. Ther.10(5), 467–470 (2010).
   PubMed Web of Science ®Google Scholar
• Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–3, CA 72–4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol.22(20), 4059–4066 (2004).
   PubMed Web of Science ®Google Scholar
• Tamimi RM, Brugge JS, Freedman ML et al. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res.68(1), 18–21 (2008).
   PubMed Web of Science ®Google Scholar
• Taysi S, Akcay F, Uslu C, Dogru Y, Gulcin I. Trace elements and some extracellular antioxidant protein levels in serum of patients with laryngeal cancer. Biol. Trace Elem. Res.91(1), 11–18 (2003).
   PubMed Web of Science ®Google Scholar
• Haouas H, Haouas S, Uzan G, Hafsia A. Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology15(4), 193–203 (2010).
   PubMed Web of Science ®Google Scholar
• Osunkoya AO, Yin-Goen Q, Phan JH et al. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. Hum. Pathol.40(12), 1671–1678 (2009).
   PubMed Web of Science ®Google Scholar
• Vose JM, Colcher D, Gobar L et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin’s lymphoma. Leuk. Lymphoma38(1–2), 91–101 (2000).
   PubMed Web of Science ®Google Scholar
• Cao Y, Veitonmaki N, Keough K et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int. J. Mol. Med.5(5), 547–551 (2000).
   PubMed Web of Science ®Google Scholar
• Strojan P, Budihna M, Smid L et al. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma48(1), 66–71 (2001).
   PubMed Web of Science ®Google Scholar
• Lee MJ, Yu GR, Park SH et al. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin. Cancer Res.14(4), 1080–1089 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC, Jr., Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res.64(16), 5882–5890 (2004).
   PubMed Web of Science ®Google Scholar
• Farias-Eisner G, Su F, Robbins T et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am. J. Obstet. Gynecol.202(1), 73 e71–e75 (2010).
   PubMedGoogle Scholar
• McKinney KQ, Lee YY, Choi HS et al. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J. Proteomics74(1), 79–88 (2011).
   PubMed Web of Science ®Google Scholar
• Shi Q, Harris LN, Lu X et al. Declining plasma fibrinogen α fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J. Proteome Res.5(11), 2947–2955 (2006).
   PubMed Web of Science ®Google Scholar
• Tesarova P, Kvasnicka J, Umlaufova A et al. [Acute phase proteins in female patients with breast carcinoma]. Sb Lek.104(2), 121–132 (2003).
   PubMedGoogle Scholar
• Bachtiar I, Santoso JM, Atmanegara B et al. Combination of α-1-acid glycoprotein and α-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin. Chim. Acta399(1–2), 97–101 (2009).
   PubMed Web of Science ®Google Scholar
• Bruno R, Olivares R, Berille J et al. α-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res.9(3), 1077–1082 (2003).
   PubMed Web of Science ®Google Scholar
• Fentz AK, Sporl M, Spangenberg J et al. Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin. Appl.1(6), 536–544 (2007).
   PubMed Web of Science ®Google Scholar
• Liu L, Liu J, Wang Y et al. A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers16(1), 20–30 (2011).
   PubMed Web of Science ®Google Scholar
• Jou YJ, Lin CD, Lai CH et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal. Chim. Acta681(1–2), 41–48 (2010).
   PubMed Web of Science ®Google Scholar
• Iacobelli S, Sismondi P, Giai M et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer69(1), 172–176 (1994).
   PubMed Web of Science ®Google Scholar
• Iacovazzi PA, Trisolini A, Barletta D et al. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with α-fetoprotein. Clin. Chem. Lab. Med.39(10), 961–965 (2001).
   PubMed Web of Science ®Google Scholar
• Yeshowardhana, Singh VS. Significance of serum phosphohexose isomerase, hexokinase and aldolase in carcinoma ovary. Indian J. Physiol. Pharmacol.29(1), 51–54 (1985).
   PubMedGoogle Scholar
• Strojan P, Oblak I, Svetic B, Smid L, Kos J. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br. J. Cancer90(10), 1961–1968 (2004).
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Ozaki Y, Nakanishi T et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol. Oncol.92(3), 881–886 (2004).
   PubMed Web of Science ®Google Scholar
• Chang KP, Wu CC, Chen HC et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics10(14), 2644–2660 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu YY, Takashi M, Miyake K, Kato K. An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J. Urol.146(2), 469–472 (1991).
   PubMed Web of Science ®Google Scholar
• Asaka M, Kimura T, Nishikawa S, Miyazuki T, Alpert E. Decreased serum aldolase B levels in patients with malignant tumors. Cancer62(12), 2554–2557 (1988).
   PubMed Web of Science ®Google Scholar
• Mikami Y, Hata S, Kiyokawa T, Manabe T. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod. Pathol.15(9), 923–930 (2002).
   PubMed Web of Science ®Google Scholar
• Dall’Era MA, True LD, Siegel AF et al. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol.7, 3 (2007).
   PubMedGoogle Scholar
• Vizan P, Sanchez-Tena S, Alcarraz-Vizan G et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis30(6), 946–952 (2009).
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Mecule A, Pasimeni G et al. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. J. Exp. Clin. Cancer Res.29, 166 (2010).
   PubMedGoogle Scholar
• Kwak JY, Ma TZ, Yoo MJ et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp. Hematol.32(9), 836–842 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes SJ, Glover TW, Zhu XX et al. A novel amplicon at 8p22–23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl Acad. Sci. USA95(21), 12410–12415 (1998).
   PubMed Web of Science ®Google Scholar
• Poon RT, Chung KK, Cheung ST et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res.10(12 Pt 1), 4150–4157 (2004).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Youssef RF, Gupta A et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J. Urol.183(5), 1744–1750 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Cao WH, Xie JJ et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer9, 291 (2009).
   PubMed Web of Science ®Google Scholar
• Oka R, Sasagawa T, Ninomiya I et al. Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma. Eur. J. Cancer37(9), 1158–1165 (2001).
   PubMed Web of Science ®Google Scholar
• Garnero P, Buchs N, Zekri J et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer82(4), 858–864 (2000).
   PubMed Web of Science ®Google Scholar
• Chen C, Mendez E, Houck J et al. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev.17(8), 2152–2162 (2008).
   PubMed Web of Science ®Google Scholar
• Tomasini-Johansson BR, Sundberg C, Lindmark G, Gailit JO, Rubin K. Vitronectin in colorectal adenocarcinoma – synthesis by stromal cells in culture. Exp. Cell Res.214(1), 303–312 (1994).
   PubMed Web of Science ®Google Scholar
• Kadowaki M, Sangai T, Nagashima T et al. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J. Cancer Res. Clin. Oncol. DOI: 10.1007/s00432-010-0974-9 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Jung K, Lein M, Stephan C et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer111(5), 783–791 (2004).
   PubMed Web of Science ®Google Scholar
• Tomonaga T, Matsushita K, Yamaguchi S et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res.10(6), 2007–2014 (2004).
   PubMed Web of Science ®Google Scholar
• Kanoh Y, Ohtani N, Mashiko T et al. Levels of α 2 macroglobulin can predict bone metastases in prostate cancer. Anticancer Res.21(1B), 551–556 (2001).
   PubMed Web of Science ®Google Scholar
• Mazouni C, Baggerly K, Hawke D et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics10(19), 3525–3532 (2010).
   PubMed Web of Science ®Google Scholar
• Meyer PR, Krugliak L, Neely S et al. Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic α-1-anti-chymotrypsin and α-1-anti-trypsin as possible indicators of early granulocytic differentiation. Am. J. Clin. Pathol.86(4), 461–468 (1986).
   PubMed Web of Science ®Google Scholar
• Kloth JN, Gorter A, Fleuren GJ et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J. Pathol.215(3), 222–230 (2008).
   PubMed Web of Science ®Google Scholar
• Comunale MA, Rodemich-Betesh L, Hafner J et al. Linkage specific fucosylation of α-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One5(8), e12419 (2010).
   Google Scholar
• Griffiths TR, Brotherick I, Bishop RI et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br. J. Cancer74(4), 579–584 (1996).
   PubMed Web of Science ®Google Scholar